How Germer International became Qualitest Pharmaceuticals’ near-exclusive talent partner — and helped build the team behind one of generic pharma’s biggest sales.
| Client | Qualitest Pharmaceuticals (formerly Vintage Pharmaceuticals) |
|---|---|
| Industry | Generic pharmaceutical manufacturing |
| Partnership | 2005–2010 (5 years) |
| Germer’s Focus | Quality Assurance and executive leadership search, near-exclusive engagement |
| Placements | ~ 110 professionals, including 6 executive-level hires |
| Outcome | Sold to Endo International for approx. $1.2 billion (2010) |
THE CHALLENGE
Founded in Huntsville, Alabama in 1983 by William S. Propst, Sr., Qualitest built a reputation as one of the top ten generic drug suppliers in the United States by prescriptions filled. But the company was operating under a consent decree that forced its founder out of day-to-day operations — putting pressure on new ownership to professionalize quickly, particularly in the quality function regulators scrutinize most closely. At the time, the company was relying on a mix of internal recruiting and a generalist search firm, neither built specifically around life sciences talent.
THE APPROACH
Germer International’s relationship with the company started with a single Quality Assurance placement that came through a referral. “We got them one QA person,” says founder and CEO John Germer. “and then a couple more. And then the HR guy said, ‘I feel like you’re on a different level ’” The company scaled back its use of other recruiters and, without Germer ever asking for it, made the firm its near-exclusive search partner.
Over the following five years, Germer’s recruiters — trained entirely in-house, with no prior outside recruiting experience — placed roughly 110 professionals at Qualitest, including six executive-level leaders spanning the C-suite down to analytical chemistry roles. Germer estimates that represents close to a quarter of the company’s professional workforce at the time of its sale — a remarkable pace of hiring in a five-year window. The firm’s approach goes beyond matching résumés to job descriptions,
John says:
“You have to find out what specifically sells for that position… it’s not just money.”
For candidates weighing a move to a lesser-known generics manufacturer, that meant surfacing — and directly addressing — the real objections keeping them at bigger, safer-sounding companies.
THE RESULT
Under new ownership, Qualitest grew from roughly 300–400 employees to more than 1,000 — a three-to-four-fold increase — while building the quality and leadership bench that institutional buyers look for. Apax Partners, which had acquired the company for approximately $1 billion, sold Qualitest to Endo International in 2010 for approximately $1.2 billion, an estimated $200 million gain on the investment.
“We’re not in this game so that we can make one placement. 97% of our revenue comes from companies that have hired us three or more times. We want to show that we can do it, and we want to win the exclusive. I have never asked for an exclusive relationship— they just end up being that way.”
— John Germer, Founder & CEO, Germer International
Germer International is applying the same playbook today with other generic pharmaceutical manufacturers and life sciences companies working toward similar outcomes.
* * *
Germer International specializes in executive and professional search for pharmaceutical, biotech, medical device, and nutraceutical companies. Germer International also partners with Private Equity and Venture investors in the space to help mitigate risk and find the best talent to spur growth and stability at their portfolio companies. To learn how Germer’s approach could support your next stage of growth, contact the firm today.

